AI Safety

Nectome Offers Last Discount on Brain Preservation Before 2026 Launch

Nectome Offers Last Discount on Brain Preservation Before 2026 Launch

⚡A company that preserves your brain after death is now taking sign-ups—but it's not for everyone.

Deep Dive

Nectome, a startup that aims to preserve your brain after death so it could theoretically be revived in the future, is offering its last-ever discount to individual customers. The company says it's been overwhelmed by support from the rationalist community and wants to give everyone one more chance to buy in before its official launch in January 2026. After that, they say they'll never offer this deal to individuals again.

The company has grown significantly in 2026: it doubled its team, moved to a bigger office, and expanded its lab. It also secured about $3 million from Lightcone Commons to research more flexible preservation methods—like allowing hospice deaths instead of only medically assisted deaths. Currently, Nectome's procedure must be performed within 12 minutes of death, and only under specific conditions.

Nectome has also built a new mobile preservation lab (version 3.0), which it describes as looking like the bridge of the starship Enterprise and being much less janky than the previous version. It's wheelchair-accessible and has more automated features. The company also found a private, comfortable location for clients to spend their final days with family before preservation. And earlier this year, it completed its first paid preservation—of a family dog with terminal cancer.

The catch: Nectome's procedure is still highly experimental and only available under narrow conditions. It's not a proven way to achieve immortality, and the science of reviving a preserved brain is far from settled. The company is also secretive about its methods and location, citing trade secrets. For now, this is a costly gamble on a very uncertain future.

Key Points
  • Nectome is offering a final discount on brain preservation before its January 2026 launch.
  • The company has doubled in size and secured $3 million to make preservation more flexible.
  • The procedure is still experimental, expensive, and only works for people who choose medically assisted death.

Why It Matters

This is a high-risk, high-cost bet on future technology that may never work—and it's not for everyone.

📬 Get the top 10 AI stories daily